MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 563586 | Name: Ranitidine-N-oxide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ranitidine-N-oxide is a metabolite of Ranitidine, also known as Zantac. Ranitidine is a histamine H2-receptor antagonist, inhibiting the normal and meal-stimulated secretion of stomach acid. Ranitidine decreases stomach acid production.

Chemical Structure

Ranitidine-N-oxide
Ranitidine-N-oxide
CAS#73857-20-2

Theoretical Analysis

MedKoo Cat#: 563586

Name: Ranitidine-N-oxide

CAS#: 73857-20-2

Chemical Formula: C13H22N4O4S

Exact Mass: 330.1362

Molecular Weight: 330.40

Elemental Analysis: C, 47.26; H, 6.71; N, 16.96; O, 19.37; S, 9.70

Price and Availability

Size Price Availability Quantity
10mg USD 750.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Ranitidine-N-oxide, Ranitidine N oxide, zantac
IUPAC/Chemical Name
1,1-Ethenediamine, N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-, N-oxide
InChi Key
PPCOGEBVJJMLBW-UKTHLTGXSA-N
InChi Code
InChI=1S/C13H22N4O4S/c1-14-13(9-17(19)20)16(18)6-7-22-10-12-5-4-11(21-12)8-15(2)3/h4-5,9,14,16H,6-8,10H2,1-3H3/b13-9+
SMILES Code
O=[N+](/C=C(NC)/[NH+]([O-])CCSCC1=CC=C(CN(C)C)O1)[O-]
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>3 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Ranitidine N-oxide is a N-oxide derivative of ranitidine. It has a role as a marine xenobiotic metabolite and a drug metabolite. It is a member of furans, a C-nitro compound and a N-oxide.
In vitro activity:
Ranitidine inhibited [3H]-tiotidine binding and histamine-stimulated cAMP production. These findings demonstrate that ranitidine inhibits the human histamine H2 receptor very rapidly. Reference: Digestion. 2003;68(2-3):145-52. https://pubmed.ncbi.nlm.nih.gov/14671421/
In vivo activity:
Ranitidine reduces tumor-associated immune suppression allowing for the development of more effective antitumor responses mediated by B cells which may include the participation of NK cells. Reference: Front Immunol. 2018 Aug 15;9:1894. https://pubmed.ncbi.nlm.nih.gov/30158936/

Preparing Stock Solutions

The following data is based on the product molecular weight 330.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Fukushima Y, Ishikawa T, Saitoh T, Tateishi K, Ogihara T, Fujishiro M, Shojima N, Honda M, Kushiyama A, Anai M, Sakoda H, Ono H, Onishi Y, Otsuka H, Katagiri H, Nagai R, Omata M, Asano T. Extremely early onset of ranitidine action on human histamine H2 receptors expressed in HEK293 cells. Digestion. 2003;68(2-3):145-52. doi: 10.1159/000075349. Epub 2003 Dec 10. PMID: 14671421. 2. Collett A, Higgs NB, Sims E, Rowland M, Warhurst G. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther. 1999 Jan;288(1):171-8. PMID: 9862768. 3. Rogers D, Vila-Leahey A, Pessôa AC, Oldford S, Marignani PA, Marshall JS. Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response. Front Immunol. 2018 Aug 15;9:1894. doi: 10.3389/fimmu.2018.01894. PMID: 30158936; PMCID: PMC6104125. 4. Chung WG, Park CS, Roh HK, Lee WK, Cha YN. Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20. doi: 10.1254/jjp.84.213. PMID: 11128045.
In vitro protocol:
1. Fukushima Y, Ishikawa T, Saitoh T, Tateishi K, Ogihara T, Fujishiro M, Shojima N, Honda M, Kushiyama A, Anai M, Sakoda H, Ono H, Onishi Y, Otsuka H, Katagiri H, Nagai R, Omata M, Asano T. Extremely early onset of ranitidine action on human histamine H2 receptors expressed in HEK293 cells. Digestion. 2003;68(2-3):145-52. doi: 10.1159/000075349. Epub 2003 Dec 10. PMID: 14671421. 2. Collett A, Higgs NB, Sims E, Rowland M, Warhurst G. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther. 1999 Jan;288(1):171-8. PMID: 9862768.
In vivo protocol:
1. Rogers D, Vila-Leahey A, Pessôa AC, Oldford S, Marignani PA, Marshall JS. Ranitidine Inhibition of Breast Tumor Growth Is B Cell Dependent and Associated With an Enhanced Antitumor Antibody Response. Front Immunol. 2018 Aug 15;9:1894. doi: 10.3389/fimmu.2018.01894. PMID: 30158936; PMCID: PMC6104125. 2. Chung WG, Park CS, Roh HK, Lee WK, Cha YN. Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20. doi: 10.1254/jjp.84.213. PMID: 11128045.
1: Park CS, Kang JH, Chung WG, Yi HG, Pie JE, Park DK, Hines RN, McCarver DG, Cha YN. Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effects on in vivo and in vitro FMO activities. Pharmacogenetics. 2002 Jan;12(1):77-80. doi: 10.1097/00008571-200201000-00011. PMID: 11773868. 2: Chung WG, Park CS, Roh HK, Lee WK, Cha YN. Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20. doi: 10.1254/jjp.84.213. PMID: 11128045. 3: Kang JH, Chung WG, Lee KH, Park CS, Kang JS, Shin IC, Roh HK, Dong MS, Baek HM, Cha YN. Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population. Pharmacogenetics. 2000 Feb;10(1):67-78. doi: 10.1097/00008571-200002000-00009. PMID: 10739174. 4: Viñas P, Campillo N, López-Erroz C, Hernández-Córdoba M. Use of post-column fluorescence derivatization to develop a liquid chromatographic assay for ranitidine and its metabolites in biological fluids. J Chromatogr B Biomed Sci Appl. 1997 Jun 6;693(2):443-9. doi: 10.1016/s0378-4347(97)00075-3. PMID: 9210451. 5: Davies MH, Ngong JM, Pean A, Vickers CR, Waring RH, Elias E. Sulphoxidation and sulphation capacity in patients with primary biliary cirrhosis. J Hepatol. 1995 May;22(5):551-60. doi: 10.1016/0168-8278(95)80450-1. PMID: 7650336. 6: Cross DM, Bell JA, Wilson K. Kinetics of ranitidine metabolism in dog and rat isolated hepatocytes. Xenobiotica. 1995 Apr;25(4):367-75. doi: 10.3109/00498259509061858. PMID: 7645303. 7: Ballard P, Law B. Chromatographic retention relationships between aliphatic tertiary amines and their putative N-oxide metabolites--preliminary results. J Pharm Biomed Anal. 1990;8(8-12):877-80. doi: 10.1016/0731-7085(90)80136-d. PMID: 2100636. 8: Prueksaritanont T, Sittichai N, Prueksaritanont S, Vongsaroj R. Simultaneous determination of ranitidine and its metabolites in human plasma and urine by high-performance liquid chromatography. J Chromatogr. 1989 May 5;490(1):175-85. doi: 10.1016/s0378-4347(00)82772-3. PMID: 2760148. 9: Rahman A, Hoffman NE, Rustum AM. Determination of ranitidine in plasma by high-performance liquid chromatography. J Pharm Biomed Anal. 1989;7(6):747-53. doi: 10.1016/0731-7085(89)80119-0. PMID: 2490777. 10: Lant MS, Martin LE, Oxford J. Qualitative and quantitative analysis of ranitidine and its metabolites by high-performance liquid chromatography-mass spectrometry. J Chromatogr. 1985 Apr 17;323(1):143-52. doi: 10.1016/s0021-9673(01)90379-6. PMID: 4008551. 11: Tamura J, Sato N, Ezaki H, Miyamoto H, Oda S, Hirai K, Tokado H, Matsumoto M, Shirai T. [Acute toxicity of ranitidine and its metabolite in mice, rats and rabbits, and subacute oral toxicity of ranitidine in rats]. J Toxicol Sci. 1983 Jan;8 Suppl 1:1-24. Japanese. doi: 10.2131/jts.8.supplementi_1. PMID: 6134840. 12: Martin LE, Oxford J, Tanner RJ. Use of high-performance liquid chromatography-mass spectrometry for the study of the metabolism of ranitidine in man. J Chromatogr. 1982 Apr 9;251(2):215-24. doi: 10.1016/s0021-9673(00)98519-4. PMID: 6284777. 13: Martin LE, Oxford J, Tanner RJ. The use of on-line high-performance liquid chromatography-mass spectrometry for the identification of ranitidine and its metabolites in urine. Xenobiotica. 1981 Dec;11(12):831-40. doi: 10.3109/00498258109045320. PMID: 6281996. 14: Carey PF, Martin LE, Owen PE. Determination of ranitidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography. J Chromatogr. 1981 Sep 11;225(1):161-8. doi: 10.1016/s0378-4347(00)80255-8. PMID: 6271798.